Search

Velmanase alfa

Patients with alpha-mannosidosis have a genetic mutation that causes a deficiency in the lysosomal enzyme alpha-mannosidase, which is an enzyme responsible for breaking down complex sugars in the body. … [A244509] In February 2023, the FDA also approved velmanase alfa for the same indication.[L45295] Velmanase alfa is currently not approved in Canada.

Sotrovimab

found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting. … [L41369] Sotrovimab was granted marketing authorization in the European Union in December 2021 under the brand name Xevudy.[L39625,L39620]

Difelikefalin

Difelikefalin (CR845) is an agonist of kappa opioid receptors (KORs) useful in the treatment of pruritus secondary to chronic kidney disease. KORs were first associated with itching in 1984. … [A237615,A237620] The clinical burden of uremic pruritus in this patient population is being increasingly recognized as contributing to a significant reduction in patient quality of life, poor outcomes

Chlorine

It was also used in chemical warfare and in rocket fuel. … Being a yellow-green gas at room temperature, chlorine is the second most abundant halogen on Earth. It is commonly used in sanitation, disinfection and antiseptic processes.

Siponimod

[L5801] MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] … It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020.

Corticorelin ovine triflutate

If corticorelin injection results in an increase of plasma ACTH and cortisol, the patient is diagnosed with Cushing's disease. … However, if corticorelin injection does not result in an increase of plasma ACTH and cortisol, the patient is diagnosed with ectopic ACTH syndrome.

Procaine

(From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). Procaine has also been investigated as an oral entry inhibitor in treatment-experienced HIV patients [L1215].

Catumaxomab

Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency. … Catumaxumab was approved for market in Canada in May 2012 for the same condition [FDA Label]. It is currently available under the brand name Removab.

Clostridium tetani

Tiotropium

[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation. … [A180163] Tiotropium was granted FDA approval on 30 January 2004.[L7084]